Isoprinosine along with Favipiravir or Oseltamivir in Patients with Moderate Covid-19 at RSD Dr. Soebandi Jember
Downloads
Background: Isoprinosine is an immunomodulator that is now being used to treat Covid-19 patients. Objectives: To evaluate Isoprinosine with Favipiravir or Oseltamivir in moderate Covid-19. Methods: In a retrospective observational analysis, in-hospital moderate Covid-19 patients treated between June 2020 and June 2021 were included. Results: Inclusion criteria for 364 patients were met, with 135 receiving Favipiravir-Isoprinosine (Group 1) and 229 receiving Oseltamivir-Isoprinosine (Group 2). In group 1, the majority of patients (58.50%) were female (35.60%), had no comorbidities (71.60%), were discharged with a positive PCR (74.80%), did not require a breathing apparatus (99.26%), had leukocyte levels between 4,5-11,0 (82.22%), lymphocyte levels between 25-33 (34.07%), and were discharged with no ground-glass opacity (34.07%) (54.10%), LOS was 9-13 days (50.37%), while the mortality rate was 0.70%. In group 2, the majority of patients were male (54.10%), with the highest age range being 42-56 years (35.80%), without comorbidities (69.0%), discharged with a positive PCR (72.50 %), and without the need for a breathing apparatus (99.13%), with leukocyte levels ranging from 4.5 – 11.0 (81.22 %), with lymphocyte levels ranging from 25.0 – 33.0 (26.20 %), and were discharged with no ground-glass opacity (49.34 %), LOS was 9 - 13 days (34.06 %), and the mortality rate was 0.87%.Conclusion: In this trial, it was determined that combining isoprinosine with antivirals favipiravir or Oseltamivir could produce significant clinical improvement.
Aksel, G., Ä°slam, M. M., Algın, A., Eroğlu, S. A., Yaşar, G. B., Ademoğlu, E. & Dölek, U. C. (2021). Early Predictors of Mortality for Moderate to Severely Ill Patients with Covid-19. American Journal of Emergency Medicine; 45; 290–296. doi: 10.1016/j.ajem.2020.08.076.
Amsden, G. W., Baird, I. M., Simon, S. & Treadway, G. (2003). Efficacy and Safety of Azithromycin Vs Levofloxacin in the Outpatient Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis. Chest; 123; 772–777. doi: 10.1378/chest.123.3.772.
Beran, J., Å pajdel, M., Katzerová, V., HolouÅ¡ová, A., MalyÅ¡, J., Rousková, J. F. & Slíva, J. (2020). Inosine Pranobex Significantly Decreased the Case-Fatality Rate Among PCR Positive Elderly with SARS-CoV-2 at Three Nursing Homes in the Czech Republic. Pathogens; 9; 1-10. doi: 10.3390/pathogens9121055.
Beran, J., Å pajdel, M. & Slíva, J. (2021). Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the Covid-19 Disease Course. Viruses; 13; 1-13. doi: 10.3390/v13112246.
Biswas, M., Rahaman, S., Biswas, T. K., Haque, Z. & Ibrahim, B. (2021). Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology; 64; 36–47. doi: 10.1159/000512592.
Burhan, E., Susanto, A. D., Isbaniah, F., Nasution, S. A., Ginanjar, E., Pitoyo, C. W., Susilo, A. et al. (2020). Pedoman Tatalaksana Covid-19 Edisi 3. In Erlina Burhan, Agus Dwi Susanto, Fathiyah Isbaniah, Sally Aman Nasution, E. et al. (eds). Jakarta: Perhimpunan Dokter Paru Indonesia (PDPI), Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia (IDAI).
Chiba, S. (2021). Effect of Early Oseltamivir on Outpatients without Hypoxia with Suspected COVID-19. Wiener Klinische Wochenschrift; 133; 292–297. doi: 10.1007/s00508-020-01780-0.
Ciarambino, T., Para, O. & Giordano, M. (2021) Immune System and COVID-19 by Sex Differences and Age. Women's Health; 17; 1-6. doi: 10.1177/17455065211022262.
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group & Eggo, R. M. (2020). Age-Dependent Effects in the Transmission and Control of COVID-19 Epidemics. Nature Medicine; 26; 1205–1211. doi: 10.1038/s41591-020-0962-9.
Dluholucky, S. (2020). Inosine Pranobex (IP) - Possibilities of Its Use in the Treatment of COVID19. Archives of Community Medicine and Public Health; 6; 200–201. doi: 10.17352/2455-5479.000106.
Finberg, R. W., Ashraf, M., Julg, B., Ayoade, F., Marathe, J. G., Issa, N. C., Wang, J. P., Jaijakul, S., Baden, L. R. & Epstein, C. (2021). US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. Open Forum Infectious Diseases; 8; 1-8. doi: 10.1093/ofid/ofab563.
Instiaty, Darmayani, I. G. A. A. P. S., Marzuki, J. E., Angelia, F., William, Siane, A., Sary, L. D., Yohanes, L., Widyastuti, R., Nova, R., Simorangkir, D. S., Lonah, Safitri, Y., Aliska, G. & Gayatri, A. (2020). Antiviral Treatment of COVID-19: a Clinical Pharmacology Narrative Review. Medical Journal of Indonesia; 29; 332–345. doi: 10.13181/mji.rev.204652.
Jafarzadeh, A., Jafarzadeh, S., Nozari, P., Mokhtari, P. & Nemati, M. (2021). Lymphopenia an Important Immunological Abnormality in Patients with COVID-19: Possible Mechanisms. Scandinavian Journal of Immunology; 93; 1–16. doi: 10.1111/sji.12967.
Lasek, W., Janyst, M., Wolny, R., ZapaÅ‚a, L., Bocian, K. & Drela, N. (2015). Immunomodulatory Effects of Inosine Pranobex on Cytokine Production by Human Lymphocytes. Acta Pharmaceutica; 65; 171–180. doi: 10.1515/acph-2015-0015.
Long, L., Wu, L., Chen, L., Zhou, D., Wu, H., Lu, D., Li, H., Duan, X., Han, Y., Li, X., Wang, Q. & Zhang, J. (2021). Effect of Early Oxygen Therapy and Antiviral Treatment on Disease Progression in Patients with COVID-19: A Retrospective Study of Medical Charts in China. PLoS Neglected Tropical Diseases; 15; 1–15. doi: 10.1371/journal.pntd.0009051.
Mortaz, E., Tabarsi, P., Varahram, M., Folkerts, G., Adcock, I. M. (2020). The Immune Response and Immunopathology of COVID-19. Frontiers in Immunology; 11; 1–9. doi: 10.3389/fimmu.2020.02037.
Özlüşen, B., Kozan, S., Akcan, R. E., Kalender, M., Yaprak, D., Peltek, I. B., Keske, S., Gönen, M. & Ergönül, O. (2021). Effectiveness of favipiravir in COVID-19: A Live Systematic Review. European Journal of Clinical Microbiology and Infectious Diseases; 40; 2575–2583. doi: 10.1007/s10096-021-04307-1.
Pan, F., Ye, T., Sun, P., Gui, S., Liang, B., Li, L., Zheng, D., Wang, Z., Hesketh, R. L., Yang, L. & Zheng, C. (2020). Time Course of Lung Changes at Chest CT During Recovery from Coronavirus Disease 2019 (COVID-19). Radiology; 295; 715–721. doi: 10.1148/radiol.2020200370.
Petrova, M., Jelev, D., Ivanova, A. & Krastev, Z. (2010). Isoprinosine Affects Serum Cytokine Levels in Healthy Adults. Journal of Interferon and Cytokine Research; 30; 223-228 doi: 10.1089/jir.2009.0057.
Shannon, A., Selisko, B., Le, N-T-T., Huchting, J., Touret, F., Piorkowski, G., Fattorini, V., Ferron, F., Decroly, E., Meier, C., Coutard, B., Peersen, O. & Canard, B. (2020). Rapid Incorporation of Favipiravir by the Fast and Permissive Viral RNA Polymerase Complex Results in SARS-CoV-2 Lethal Mutagenesis. Nature Communications; 11; 1–9. doi: 10.1038/s41467-020-18463-z.
Shianata, C. M., Engka, J. N. A. & Pangemanan, D. H. C. (2021). Happy Hypoxia pada Coronavirus Disease. Jurnal Biomedik: Jbm; 13; 58–66. doi: 10.35790/jbm.13.1.2021.31743.
Sliva, J., Pantzartzi, C. N. & Votava, M. (2019). Inosine Pranobex: a Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases. Advances in Therapy; 36; 1878-1905. doi: 10.1007/s12325-019-00995-6.
Surendra, H. Elyazar, I. R. F., Djaafaraa, B. A., Ekawati, L. L., Saraswati, K., Adrianf, V., Widyastuti, Oktaviaf, D., Salamaf, N., Lina, R. N., Andrianto, A., Lestari, K. D., Burhang, E., Shankar, A. H., Thwaites, G., Bairda, K. & Hamers, R. L. (2021). Clinical Characteristics and Mortality Associated with COVID-19 in Jakarta, Indonesia: a Hospital-Based Retrospective Cohort Study. The Lancet Regional Health - Western Pacific; 9; 1-9. doi: 10.1016/j.lanwpc.2021.100108.
Vahidy, F. S., Pan, A. P., Ahnstedt, J., Munshi, Y., Choi, H. A., Tiruneh, Y., Nasir, K., Kash, B. A., Andrieni, J. D. & McCullough, L. D. (2021). Sex Differences in Susceptibility, Severity, and Outcomes of Coronavirus Disease 2019: Cross-Sectional Analysis from a Diverse US Metropolitan Area. PLoS ONE; 16; 1–14. doi: 10.1371/journal.pone.0245556.
Wang, J., Jiang, M., Chen, X. & Montaner, L. J. (2020). Cytokine Storm and Leukocyte Changes in Mild Versus Severe SARS-CoV-2 Infection: Review of 3939 COVID-19 Patients in China and Emerging Pathogenesis and Therapy Concepts. Journal of Leukocyte Biology; 108; 17–41. doi: 10.1002/JLB.3COVR0520-272R.
Yazdanpanah, F., Hamblin, M. R. & Rezaei, N. (2020). The Immune System and COVID-19: Friend or Foe?. Life Sciences; 256; 1-5.
Yuki, K., Fujiogi, M. & Koutsogiannaki, S. (2020). COVID-19 Pathophysiology: a Review Koichi. Clinical Immunology Journal; 215; 1-7.
Copyright (c) 2022 JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. The copyright of this journal belongs to the Editorial Board and Journal Manager with the author's knowledge, while the moral right of the publication belong to the author.
2. The formal legal aspect of journal publication accessibility refers to the Creative Commons Attribution-Non-Commercial-Share Alike (CC BY-NC-SA), which implies that the publication can be used for non-commercial purposes in its original form.
3. Every publication (print/electronic) is open access for educational, research, and library purposes. In addition to the objectives mentioned above, the editorial board is not responsible for copyright infringement
.jpg)
